Trinity Biotech plc
20.90%
85,800,000
888721
896438504
Dec 30, 2024
Feb 14, 2025, 04:15 PM
Reporting Persons (5)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Joseph Edelman | Individual | 20.90% | 85,800,000 | 0 | 85,800,000 |
| Perceptive Advisors LLC | Other | 20.90% | 85,800,000 | 0 | 85,800,000 |
| Perceptive Credit Advisors LLC | Other | 20.90% | 85,800,000 | 0 | 85,800,000 |
| Perceptive Credit Holdings II, L.P. | Partnership | 11.40% | 45,800,000 | 0 | 45,800,000 |
| Perceptive Credit Holdings III, L.P. | Partnership | 9.70% | 40,000,000 | 0 | 40,000,000 |
Disclosure Items (2)
Class A Ordinary Shares, $0.0109 par value per share
Trinity Biotech plc
IDA Business Park, Co. Wicklow, L2, A98 H5C8
Items 5(a)-(b) of the Schedule 13D is amended and supplemented as follows: The information set forth in rows 11 and 13 of the cover pages to this Amendment No. 3 to the Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 361,073,562 Ordinary Shares outstanding as of November 30, 2024, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(3) with the Securities and Exchange Commission on December 5, 2024, and, with respect to Credit Fund II, assumes the exercise of 500,000 Warrants held by Credit Fund II into 500,000 ADSs representing 10,000,000 Ordinary Shares, and with respect to Credit Fund III, assumes the exercise of 2,000,000 Warrants held by Credit Fund III into 2,000,000 ADSs representing 40,000,000 Ordinary Shares.
The information set forth in rows 7 through 10 of the cover pages to this Amendment No. 3 to the Schedule 13D is incorporated by reference.